Evidence map›Paper›PMID 27844137›Full record

ReviewHerz2017

[Clinical importance of HDL cholesterol].

W März, M E Kleber, H Scharnagl, T Speer, S Zewinger, A Ritsch, K G Parhofer, A von Eckardstein, U Landmesser, U Laufs

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. [Laboratory diagnostics of lipid metabolism disorders].Deutsche medizinische Wochenschrift (1946) · 2023
    Article
  4. Article
  5. Article
  6. HDL cholesterol: reappraisal of its clinical relevance.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

W MärzMedizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Deutschland.
M E KleberMedizinische Klinik V (Nephrologie, Hypertensiologie, Rheumatologie, Endokrinologie, Diabetologie), Medizinische Fakultät Mannheim der Universität Heidelberg, Heidelberg, Deutschland.
H ScharnaglKlinisches Institut für Medizinische und Chemische Labordiagnostik, Medizinische Universität Graz, Graz, Österreich.
T SpeerKlinik für Innere Medizin IV, Nieren- und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Deutschland.
S ZewingerKlinik für Innere Medizin IV, Nieren- und Hochdruckkrankheiten, Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Deutschland.
A RitschKlinik für Innere Medizin, Medizinische Universität Innsbruck, Innsbruck, Österreich.
K G ParhoferMedizinische Klinik II, Klinikum der Universität München, 81377, München, Deutschland.
A von EckardsteinInstitut für Klinische Chemie, Universitätsspital, 8091, Zürich, Schweiz.
U LandmesserKlinik für Kardiologie, Charité, Berlin, Deutschland.
U LaufsKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin (IMED), Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Deutschland. ulrich.laufs@uks.eu.
Universitätsklinikum des Saarlandes · DEMedical University of Graz · ATCharité - Universitätsmedizin Berlin · DEInnsbruck Medical University · ATLMU Klinikum · DEMedizinische Fakultät Mannheim

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backroundEach year 16-17 million determinations of high-density lipoprotein cholesterol (HDL-C) are conducted and interpreted in Germany. Recently acquired data have led to a fundamental reassessment of the clinical significance of HDL-C.

methodThis review article is based on a selective literature search.

resultsLow HDL‑C levels usually indicate an increased cardiovascular risk, particularly in primary prevention but the epidemiological relationship between HDL‑C and the risk is complex. The HDL plays a role in the back transport and excretion of cholesterol; however, the biological functions of HDL are dependent on the protein and lipid composition, which is not reflected by the HDL‑C concentration. If the composition of HDL is pathologically altered it can also exert negative vascular effects.

conclusionCompared with low-density lipoprotein cholesterol (LDL-C), HDL‑C is of secondary importance for cardiovascular risk stratification and the calculation of the LDL-C:HDL‑C ratio is not useful for all patients. Low HDL‑C levels should prompt a search for additional metabolic and inflammatory pathologies. An increase in HDL‑C through lifestyle changes (e.g. smoking cessation and physical exercise) has positive effects and is recommended; however, HDL‑C is currently not a valid target for drug therapy.

Indexed as

BiomarkersCardiovascular DiseasesCholesterol, HDLCholesterol, LDLEvidence-Based MedicineHumansPrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityBiomarkersCholesterol, HDLCholesterol, LDLCardiovascular riskCholesterolHigh-density lipoproteinLow-density lipoproteinReview

Identifiers

PMID27844137
OpenAlexW2564685884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.